EpiCast Report: Heart Failure – Epidemiology Forecasts to 2026

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Heart failure (HF), also referred to as congestive cardiac failure, is a heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic needs of the body. Eventually, without the heart's pumping action to deliver oxygen and nutrient-rich blood to the cells, fatigue, shortness of breath, and coughing results. Even everyday activities such as walking, climbing stairs, or carrying weight can become tedious.

To forecast the diagnosed incident cases of HF and diagnosed prevalent cases of CHF in the 7MM, GlobalData epidemiologists selected the best available nationally representative data ascertained through an exhaustive literature search.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of HF will increase from 1,990,569 cases in 2016 to 2,468,827 cases in 2026 at an annual growth rate (AGR) of 2.40%. The US had the highest number of diagnosed incident cases of HF in the 7MM in both 2016 and 2026, at 827,525 cases in 2016, and 1,081,878 cases in 2026.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of CHF will increase from 14,403,423 cases in 2016 to 17,127,297 cases in 2026 at an AGR of 1.89%. The US had the highest number of diagnosed prevalent cases of CHF in the 7MM in both 2016 and 2026, at 5,816,242 cases in 2016, and 7,115,415 cases in 2026.

Scope

The Heart Failure (HF) EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of HF in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of HF, diagnosed incident cases of HF segmented by ejection fraction and ventricular dysfunction, acute HF hospitalizations, acute HF hospitalizations by worsening HF, advanced HF, and de novo HF, and acute HF hospitalization by patients admitted and discharged, hospital length of stay for acute HF hospitalization, diagnosed prevalent cases of chronic HF (CHF), and diagnosed prevalent cases of CHF segmented by ejection fraction. The diagnosed prevalent cases of CHF, CHF with REF, and CHF with PEF are further classified according to the New York Heart Association (NYHA) functional classes I–IV. The diagnosed incident cases of HF and diagnosed prevalent cases of CHF are segmented by age (at 10-year intervals, for ages 45 years and older) and sex.

The HF epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The Heart Failure EpiCast series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global HF market.

Quantify patient populations in the global HF market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HF therapeutics in each of the markets covered.

Understand HF cases patient distribution by ejection fraction and NYHA functional classes.

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Heart Failure: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.4.3 Diagnosed Incident Cases of HF by EF

3.4.4 Diagnosed Incident Cases of HF by Ventricular Dysfunction

3.4.5 Acute HF Hospitalizations

3.4.6 Hospital Length of Stay for Acute HF Hospitalization

3.4.7 Diagnosed Prevalent Cases of CHF

3.4.8 Diagnosed Prevalent Cases of CHF by EF

3.4.9 Diagnosed Prevalent Cases of CHF by NYHA Classes

3.5 Epidemiological Forecast for Heart Failure (2016–2026)

3.5.1 Diagnosed Incident Cases of HF

3.5.2 Age-Specific Diagnosed Incident Cases of HF

3.5.3 Sex-Specific Diagnosed Incident Cases of HF

3.5.4 Diagnosed Incident Cases of HF by EF

3.5.5 Diagnosed Incident Cases of HF by VD

3.5.6 Acute HF Hospitalizations

3.5.7 Hospital Length of Stay for Acute HF Hospitalization

3.5.8 Diagnosed Prevalent Cases of CHF

3.5.9 Age-Specific Diagnosed Prevalent Cases of CHF

3.5.10 Sex-Specific Diagnosed Prevalent Cases of CHF

3.5.11 Diagnosed Prevalent Cases of CHF by EF

3.5.12 Diagnosed Prevalent Cases of CHF by NYHA Class

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of Analysis

3.6.3 Strengths of Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologist

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

Table

Table 1: Risk Factors and Comorbidities for HF

Table 2: NYHA Functional Classification for CHF (Classes I–IV).

Table 3: 7MM, Diagnosed Incident Cases of HF, Both Sexes, Ages ≥45 Years, N, Selected Years 2016–2026

Table 4: 7MM, Diagnosed Prevalent Cases of CHF, Both Sexes, Ages ≥45 Years, N, Selected Years 2016–2026

Figures

Figure 1: 7MM, Diagnosed Incident Cases of HF, Both Sexes, Ages ≥45 Years, 2016 and 2026

Figure 2: 7MM, Diagnosed Prevalent Cases of CHF, Both Sexes, Ages ≥45 Years, 2016 and 2026

Figure 3: 7MM, Age-Standardized Diagnosed Incidence of HF (Cases per 100,000 Population), Men and Women, Ages ≥45 Years, 2016

Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of CHF (%), Men and Women, Ages ≥45 Years, 2016

Figure 5: 7MM, Sources Used to Forecast Diagnosed Incident Cases of HF

Figure 6: 7MM, Sources Used and Not Used to Forecast Diagnosed Prevalent Cases of CHF

Figure 7: 7MM, Sources Used to Forecast Diagnosed Incident Cases of HF by EF

Figure 8: 7MM, Sources Used to Forecast Diagnosed Prevalent Cases of CHF by EF

Figure 9: 7MM, Sources Used to Forecast Diagnosed Incident Cases of HF by Ventricular Dysfunction

Figure 10: 7MM, Sources Used to Forecast Hospitalizations for Acute HF

Figure 11: 7MM, Sources Used to Forecast Hospitalizations for Acute HF by Worsening CHF, Advanced HF, and de novo

Figure 12: 7MM, Sources Used to Forecast Hospital Length of Stay for Acute HF Hospitalization

Figure 13: 7MM, Sources Used to Forecast Diagnosed Prevalent Cases of CHF by NYHA Class

Figure 14: 7MM, Age-Specific Diagnosed Incident Cases of HF, Both Sexes, Ages ≥45 Years, N, 2016

Figure 15: 7MM, Sex-Specific Diagnosed Incident Cases of HF, Ages ≥45 Years, N, 2016

Figure 16: 7MM, Diagnosed Incident Cases of HF by EF, Both Sexes, Ages ≥45 Years, N, 2016

Figure 17: 7MM, Diagnosed Incident Cases of HF by VD, Both Sexes, Ages ≥45 Years, N, 2016

Figure 18: 7MM, Acute HF Hospitalizations, Both Sexes, Ages ≥45 Years, N, 2016 to 2026

Figure 19: 7MM, Acute HF Hospitalizations by Patients Admitted and Discharged, Both Sexes, Ages ≥45 Years, 2016

Figure 20: 7MM, Acute HF Hospitalizations by Worsening Chronic HF, Advanced HF, and De Novo HF, Both Sexes, Ages ≥45

Figure 21: 7MM, Hospital Length of Stay for Acute HF Hospitalization, Both Sexes, Ages ≥45 Years, N, 2016

Figure 22: 7MM, Age-Specific Diagnosed Prevalent Cases of CHF, Both Sexes, Ages ≥45 Years, N, 2016

Figure 23: 7MM, Sex-Specific Diagnosed Prevalent Cases of CHF, Both Sexes, Ages ≥45 Years, N, 2016

Figure 24: 7MM, Diagnosed Prevalent Cases of CHF by EF, Both Sexes, Ages ≥45 Years, N, 2016

Figure 25: 7MM, Diagnosed Prevalent Cases of CHF by NYHA Class, Both Sexes, Ages ≥45 Years, N, 2016

Figure 26: 7MM, Diagnosed Prevalent Cases of CHF with REF by NYHA Class, Both Sexes, Ages ≥45 Years, N, 2016

Figure 27: 7MM, Diagnosed Prevalent Cases of CHF with PEF by NYHA Class, Both Sexes, Ages ≥45 Years, N, 2016

Frequently asked questions

EpiCast Report: Heart Failure – Epidemiology Forecasts to 2026 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

EpiCast Report: Heart Failure – Epidemiology Forecasts to 2026 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at EpiCast Report: Heart Failure – Epidemiology Forecasts to 2026 in real time.

  • Access a live EpiCast Report: Heart Failure – Epidemiology Forecasts to 2026 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.